<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="sub-section" /><meta name="keywords" content="Corticosteroids: cancer; Corticosteroids: immunosuppression; Immunosuppressants: malignant disease; Prednisolone: malignant disease; Leukaemia: acute: lymphoblastic; Hodgkin’s disease; Ciclosporin: immunosuppression; Transplant rejection; Tacrolimus: immunosuppression; Sirolimus; Basiliximab; Belatacept; Antithymocyte immunoglobulin" /><meta name="IX" content="Corticosteroids: cancer; Corticosteroids: immunosuppression; Immunosuppressants: malignant disease; Prednisolone: malignant disease; Leukaemia: acute: lymphoblastic; Hodgkin’s disease; Ciclosporin: immunosuppression; Transplant rejection; Tacrolimus: immunosuppression; Sirolimus; Basiliximab; Belatacept; Antithymocyte immunoglobulin" /><title>8.2.2 Corticosteroids and other immunosuppressants: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="4782.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="4782.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=4782.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="2075.htm">8 Malignant disease and immunosuppression</a> &gt; <a href="4777.htm">8.2 Drugs affecting the immune response</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="38696.htm" title="Previous: MYCOPHENOLATE MOFETIL">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="201462.htm" title="Next: ANTITHYMOCYTE IMMUNOGLOBULIN (RABBIT)">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1 id="_4782">8.2.2 Corticosteroids and other immunosuppressants</h1><?highlighter on?><div id="pC" class="jN"><div><p><b><span>Prednisolone</span></b> (<a title=" Glucocorticoid therapy" href="4255.htm#_4255">section 6.3.2</a>) is widely used in oncology. It has a marked
antitumour effect in acute lymphoblastic leukaemia, Hodgkin’s disease, and the non-Hodgkin lymphomas. It has a role in
the palliation of symptomatic end-stage malignant disease when it
may enhance appetite and produce a sense of well-being (see also <a title="target-block: anorexia, palliative care" href="29458.htm#_120052">Prescribing in Palliative
Care</a>).</p><p>The <span>corticosteroids</span> are also powerful immunosuppressants.
They are used to prevent organ transplant rejection, and in high dose
to treat rejection episodes.</p><div id="_1199892242929"><p><b><span>Ciclosporin</span> </b> a calcineurin inhibitor, is a potent
immunosuppressant which is virtually non-myelotoxic but markedly nephrotoxic.
It has an important role in organ and tissue transplantation, for
prevention of graft rejection following bone marrow, kidney, liver, pancreas, heart,
lung, and heart-lung transplantation, and for prophylaxis and treatment
of graft-versus-host disease.</p></div><p><b><span>Tacrolimus</span></b> is also a calcineurin
inhibitor. Although not chemically related to <span>ciclosporin</span> it has a similar mode of action and side-effects, but the incidence
of neurotoxicity appears to be greater; cardiomyopathy has also been
reported. Disturbance of <span>glucose</span> metabolism also
appears to be significant.</p><p><b>Sirolimus</b> is a non-calcineurin inhibiting immunosuppressant licensed for renal
transplantation.</p><div id="_1199892023434"><p><span id="_4782.1"><b>Basiliximab</b> is a monoclonal antibody that acts as an interleukin-2
receptor antagonist and prevents T-lymphocyte proliferation; it is
used for prophylaxis of acute rejection in allogeneic renal transplantation.
It is given with <span>ciclosporin</span> and corticosteroid
immunosuppression regimens; its use should be confined
to specialist centres.</span></p></div><p><b>Belatacept</b> is a fusion protein and co-stimulation blocker that prevents T-cell
activation; it is licensed for prophylaxis of graft rejection in adults
undergoing renal transplantation who are seropositive for the Epstein-Barr
virus. It is used with interleukin-2 receptor antagonist induction,
in combination with corticosteroids and a mycophenolic acid.</p><div id="_201458"><p><b>Antithymocyte immunoglobulin</b> (rabbit) is licensed for the
prophylaxis of organ rejection in renal and heart allograft recipients
and for the treatment of corticosteroid-resistant allograft rejection
in renal transplantation. Tolerability is increased by pretreatment
with an intravenous corticosteroid and antihistamine; an antipyretic
drug such as paracetamol may also be beneficial.</p></div><div class="cN"><h2 class="cBR">NICE guidance</h2><h3 class="cBP">Immunosuppressive therapy for renal transplantation
in adults (September 2004)<br />Immunosuppressive therapy for
renal transplantation in children and adolescents (April 2006)</h3><p>For induction therapy in the prophylaxis of organ rejection,
either basiliximab or daclizumab [discontinued] are options for combining
with a calcineurin inhibitor. For each individual, ciclosporin or
tacrolimus is chosen as the calcineurin inhibitor on the basis of
side-effects.</p><p>Mycophenolate mofetil [mycophenolic acid also available but
not licensed for use in children, see <a title="preparation-group: Mycophenolic acid" href="129179.htm#_129179">Mycophenolic Acid</a>] is recommended
as part of an immunosuppressive regimen only if:</p><ul class="cBF"><li><p class="cQ">the calcineurin inhibitor is not tolerated, particularly
if nephrotoxicity endangers the transplanted kidney; <i>or</i></p></li><li><p class="cQ">there is very high risk of nephrotoxicity from the calcineurin
inhibitor, requiring a reduction in the dose of the calcineurin inhibitor
or its avoidance.</p></li></ul><p>Sirolimus is recommended as a component of immunosuppressive
regimen <b>only if</b> intolerance necessitates the withdrawal
of a calcineurin inhibitor.</p><p>These recommendations may not be consistent with the marketing
authorisation of some of the products.</p></div></div></div><?highlighter on?><div id="pS"><p>Sub-sections</p><ul class="jT"><li id="_201462"><a href="201462.htm" title="ANTITHYMOCYTE IMMUNOGLOBULIN (RABBIT)">ANTITHYMOCYTE IMMUNOGLOBULIN (RABBIT)</a></li><li id="_72819"><a href="72819.htm" title="BASILIXIMAB">BASILIXIMAB</a></li><li id="_217026"><a href="217026.htm" title="BELATACEPT">BELATACEPT</a></li><li id="_4783"><a href="4783.htm" title="CICLOSPORIN">CICLOSPORIN</a></li><li id="_106034"><a href="106034.htm" title="SIROLIMUS">SIROLIMUS</a></li><li id="_27585"><a href="27585.htm" title="TACROLIMUS">TACROLIMUS</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="38696.htm">Previous: MYCOPHENOLATE MOFETIL</a> | <a class="top" href="4782.htm#">Top</a> | <a accesskey="]" href="201462.htm">Next: ANTITHYMOCYTE IMMUNOGLOBULIN (RABBIT)</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>